0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Diabetic Macular Edema (DME) -Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-239
Home | Category |Health |Health Conditions |Endocrine Conditions
Diabetic Macular Edema Epidemiology Forecast to 2028

Diabetic Macular Edema (DME) -Epidemiology Forecast to 2028

Code: DELV-Epid-239
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Diabetic Macular Edema (DME) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Diabetic Macular Edema (DME) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Diabetic Macular Edema (DME) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Diabetic Macular Edema (DME) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Diabetic Macular Edema (DME) outlook. It also includes the explanation of changing trends of epidemiology outlining the Diabetic Macular Edema (DME) scenario.

Diabetic Macular Edema (DME) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Diabetic Macular Edema (DME) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Diabetic Macular Edema (DME) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Diabetic Macular Edema (DME) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Diabetic Macular Edema (DME)

Key assessments
• Patient Segmentation in Diabetic Macular Edema (DME)
• Diabetic Macular Edema (DME) Risk & Burden
• Factors driving growth in a specific Diabetic Macular Edema (DME) patient population

1. Report Introduction
2. Diabetic Macular Edema (DME) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Diabetic Macular Edema (DME) in 2016
2.2. Patient Share Distribution of Diabetic Macular Edema (DME) in 2028
3. Disease Background and Overview: Diabetic Macular Edema (DME)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM – By Countries
5. Epidemiology of Diabetic Macular Edema (DME) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.1.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME) *
5.1.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.1.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.4.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.4.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.4.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.5.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.5.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.5.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.6.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.6.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.6.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.7.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.7.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.7.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.8.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.8.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.8.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.9.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.9.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.9.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
6. Unmet Needs of the Diabetic Macular Edema (DME)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific


List of Tables :

Table 1: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM
Table 2: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Table 14: Diagnosed Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)

DelveInsight's "Diabetic Macular Edema (DME) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Diabetic Macular Edema (DME) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Diabetic Macular Edema (DME) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Diabetic Macular Edema (DME) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Diabetic Macular Edema (DME) outlook. It also includes the explanation of changing trends of epidemiology outlining the Diabetic Macular Edema (DME) scenario.

Diabetic Macular Edema (DME) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Diabetic Macular Edema (DME) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Diabetic Macular Edema (DME) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Diabetic Macular Edema (DME) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Diabetic Macular Edema (DME)

Key assessments
• Patient Segmentation in Diabetic Macular Edema (DME)
• Diabetic Macular Edema (DME) Risk & Burden
• Factors driving growth in a specific Diabetic Macular Edema (DME) patient population

Read More

1. Report Introduction
2. Diabetic Macular Edema (DME) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Diabetic Macular Edema (DME) in 2016
2.2. Patient Share Distribution of Diabetic Macular Edema (DME) in 2028
3. Disease Background and Overview: Diabetic Macular Edema (DME)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Diabetic Macular Edema (DME) in 7MM – By Countries
5. Epidemiology of Diabetic Macular Edema (DME) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.1.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME) *
5.1.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.1.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.4.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.4.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.4.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.5.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.5.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.5.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.6.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.6.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.6.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.7.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.7.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.7.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.8.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.8.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.8.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Diabetic Macular Edema (DME)
5.9.3. Sub-Type Specific cases of the Diabetic Macular Edema (DME)*
5.9.4. Sex- Specific Cases of the Diabetic Macular Edema (DME)*
5.9.5. Diagnosed Cases of the Diabetic Macular Edema (DME)
6. Unmet Needs of the Diabetic Macular Edema (DME)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

Read More


List of Tables :

Table 1: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM
Table 2: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Table 14: Diagnosed Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Diabetic Macular Edema (DME) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Diabetic Macular Edema (DME) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Diabetic Macular Edema (DME) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Diabetic Macular Edema (DME) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Diabetic Macular Edema (DME) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Diabetic Macular Edema (DME) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Diabetic Macular Edema (DME) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Diabetic Macular Edema (DME) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Diabetic Macular Edema (DME) in Japan (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Lukasiewicz Research Network

RELATED REPORTS

Global Diabetic Foot Ulcer Treatment Market Size Status and Forecast 2021 2027
Global Diabetic Foot Ulcer Treatment Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-25O4196
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Insulin Infusion Pumps Market Research Report 2021
Global Insulin Infusion Pumps Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-3M4699
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Blood Glucose Testing Devices Market Research Report 2021
Global Blood Glucose Testing Devices Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-13Q4387
Mon Feb 01 00:00:00 UTC 2021

Add to Cart

Global Continuous Blood Glucose Monitoring Market Research Report 2021
Global Continuous Blood Glucose Monitoring Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-31L4092
Mon Feb 01 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0